News - BridgeBio
2024年6月10日 · Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter, and Facebook to keep up with all of the latest news.
BridgeBio wins FDA Approval for cardiomyopathy treatment
6 天之前 · California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for treatment of transthyretin amyloid cardiomyopathy (ATTR …
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), …
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from …
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
2024年11月23日 · The U.S. Food and Drug Administration has approved BridgeBio's , opens new tab drug for a rare and deadly heart condition, the company said on Friday, making it the first …
BridgeBio wins FDA approval for heart disease drug
2024年11月23日 · The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the …
FDA Approves Acoramidis for ATTR-CM - ajmc.com
6 天之前 · The approval of acoramidis comes less than 10 months after BridgeBio Pharma announced the FDA’s acceptance of their New Drug Application (NDA) in February 2024. 2 …
BridgeBio Pharma's heart disease drug approved by FDA - Silicon …
6 天之前 · BridgeBio Pharma Inc. says the U.S. Food and Drug Administration (FDA) has approved the Palo Alto company's new treatment for the rare but deadly heart disease, …
BridgeBio | Press Releases
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin …
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) …
2024年5月2日 · BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and …
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
6 天之前 · BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis …